You searched for "intraocular"

1024 results found

Better outcomes from early repair of Type B blow-out fractures

This paper examines whether early, rather than late, surgical repair results in better motility outcomes for a particular subgroup of orbital floor blowout fractures. The authors divide floor fractures into Types A and B, depending on whether or not the...

Results of changed treatment for retinoblastoma

Systemic chemotherapy was adopted in Kobe in 1996. In this study the authors analyse the clinical manifestations and results of treatment for patients with retinoblastoma since then. This review is of 43 eyes of 34 patients. Those with follow-up to...

The future of binocular viewing systems?

I recently had the pleasure to visit Vision Engineering’s headquarters and manufacturing facility in Woking, UK. Vision Engineering have built an international reputation for engineering microscopes that provide 3D visualisation without the use of traditional optical eyepieces. Although the company...

Features of AMD treatment non-responders

This is a retrospective consecutive case series of 365 eyes with age-related macular degeneration (AMD) who had three monthly intravitreal aflibercept treatments for at least 12 months. Responders were defined as complete resolution of exudation, intraretinal oedema, subretinal fluid, pigment...

Why is there subretinal fluid at the macula?

This is a review article looking at the differential diagnosis of subretinal fluid in the macula that could be diagnosed as central serous chorioretinopathy (CSCR). The authors have categorised them into 12 groups: neovascular diseases, vitelliform lesions, inflammatory diseases, ocular...

Do bilateral same day intravitreal injections increase the risk of endophthalmitis?

This large retrospective cohort study reviewed all patients who had bilateral intravitreal anti-vascular endothelial growth factor (VEGF) injections between April 2012 and August 2017. There were 101,932 procedures performed in 5890 patients. The two most common indications for injections were...

Brolucizumab in age-related macular degeneration, HAWK Study

The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...

Glaucoma 2023

To skip directly to features, click the links below: Welcome from the editor - Andrew Tatham A glance into the past: tracing the history of glacoma treatment - by Petya Popova, Amrita Vallabh Diagnosis of glaucoma in the community in...

Eye Capacity: clinical need should drive ophthalmic service provision

Almost two million people in the UK suffer sight loss, a number forecast to double over coming decades. Major causes of blindness are age-related macular degeneration (AMD), glaucoma, diabetic retinopathy, cataract and uncorrected refractive error. Prevalence of these sight-threatening conditions...

A near miss

A 55-year-old gentleman presented with a ‘blurry patch’ to his left eye which he had noticed for the past two months. The visual acuity with correction was 6/5 in the right eye and 6/6 in the left eye on the...

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Preoperative povidone iodine: weighing the risks

Following on from our recent online survey, the authors examine the potential risks and benefits of diluting the concentration preoperative povidone iodine. Povidone iodine (PI) is an iodophore that has an established use as a broad-spectrum antiseptic, mainly for the...